A blue travel case of insulin injections is a ubiquitous companion for Asha Mehta (name changed), a chronic diabetes patient living in Mumbai. She loathes the idea of injecting a needle to get her daily dose but says this has become a habit over a decade. Her glucose levels go haywire if she misses her insulin shots for even a day. Many patients like Mehta long for an easier option to the injections. Cipla, India’s third largest drug maker by